{"disease":{"id":"neoplasm-glandular","name":"neoplasm glandular"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03072472","title":"BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities","phase":"NA","overall_status":"COMPLETED","enrollment_count":3221,"lead_sponsor_name":"South Tyneside and Sunderland NHS Foundation Trust","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02005965","title":"Low Rectal Cancer Study (MERCURY II)","phase":"","overall_status":"UNKNOWN","enrollment_count":542,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT04008082","title":"A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":412,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT01995942","title":"Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial","phase":"","overall_status":"UNKNOWN","enrollment_count":246,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT01037049","title":"Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":237,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT05152927","title":"Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04566952","title":"Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT04807166","title":"Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Wenjun Cheng","has_results":false},{"nct_id":"NCT07574541","title":"Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":52,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03535727","title":"A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT03562897","title":"Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT04556071","title":"Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT02897778","title":"Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT02909452","title":"Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT03911388","title":"HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05797246","title":"Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05935748","title":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06794073","title":"Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05592743","title":"Vorasidenib Expanded Access Program","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Servier","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}